Find a Doctor
Brian Morse, MD
Program: Diagnostic Imaging and Interventional Radiology
Locations: Moffitt Cancer Center
Cancer Focus: Anal Cancer, Bladder Cancer , Cholangiocarcinoma (Bile Duct Cancer), Colon Cancer, Colorectal Cancer , Esophageal Cancer , Gallbladder Cancer , Gastrointestinal Carcinoid Tumor , GIST (Gastrointestinal Stromal Tumor) , Kidney (Renal Cell) Cancer , Liver Cancer , Neuroendocrine Tumor , Pancreatic Cancer , Penile Cancer, Prostate Cancer , Rectal Cancer , Small Intestine Cancer , Stomach (Gastric) Cancer , Testicular Cancer
Dr. Morse is an Associate Member in the Diagnostic Imaging section of Moffitt Cancer Center and holds a co-appointment as an Associate Professor in the Department of Oncologic Sciences at the University of South Florida. He received a BA in Microbiology from the University of Texas at Austin and an M.D. from the University of Texas Health Science Center at San Antonio. He completed his radiology residency at the University of Texas Southwestern Medical Center at Dallas where he served as radiology chief-resident during his final year. After residency, Dr. Morse completed fellowship training in cross-sectional imaging with an emphasis in body MRI at the Mayo Clinic in Scottsdale, Arizona. Dr. Morse is a reviewer for several journals and has published multiple articles in peer-reviewed journals. His clinical expertise includes the use of computed tomography (CT), magnetic resonance imaging (MRI), radiographs and fluoroscopy to diagnose cancer and assess treatment response, particularly of the gastrointestinal and genitourinary organs. His research interests focus on imaging of neuroendocrine tumors.
Education & Training
- Diagnostic Radiology
- Mayo Clinic Arizona - Cross-Sectional Imaging
- University of Texas Southwestern Medical Center - Radiology
- University of Texas Health Science Center at San AntonioMD
- Al-Toubah T, Morse B, Strosberg J. Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms. Oncologist. 2020 Jan.25(1):e48-e52. Pubmedid: 31455747. Pmcid: PMC6964126.
- Morse B, Jeong D, Ihnat G, Silva AC. Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment. Abdom Radiol (NY). 2019 Feb.44(2):766-774. Pubmedid: 30196362.
- Barnebee D, Morse B, Strosberg JR, Pejic M, Jeong D. Cardiac Magnetic Resonance for Diagnosis of Neuroendocrine Tumor Metastases to the Right and Left Ventricles with Carcinoid Heart Disease. Case Rep Cardiol. 2019 Dec.2019:8746413. Pubmedid: 31885933. Pmcid: PMC6915124.
- Morse B, Jeong D, Thomas K, Diallo D, Strosberg JR. Magnetic Resonance Imaging of Neuroendocrine Tumor Hepatic Metastases: Does Hepatobiliary Phase Imaging Improve Lesion Conspicuity and Interobserver Agreement of Lesion Measurements?. Pancreas. 2017 Oct;46(9):1219-1224. Pubmedid: 28902795.
- Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017 Jul;46(6):715-731. Pubmedid: 28609357. Pmcid: PMC5502737.
- Cives M, Ghayouri M, Morse B, Brelsford M, Black M, Rizzo A, Meeker A, Strosberg J. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2016 Sep;23(9):759-767. Pubmedid: 27552969.
- Strosberg J, Cives M, Hwang J, Weber T, Nickerson M, Atreya C, Venook A, Kelley K, Valone T, Morse B, Coppola D, Bergsland E. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer. 2016 May;23(5):411-418. Pubmedid: 27080472. Pmcid: PMC4963225.
- Ahdallah R, Morse B, Hakam A, Shahzad MM. Pelvic squamous cell carcinoma of unknown primary: a case report and review of the literature. Eur J Gynaecol Oncol. 2016 Jul;37(3):430-433. Pubmedid: 27352581.
- Sewda K, Coppola D, Enkemann S, Yue B, Kim J, Lopez AS, Wojtkowiak JW, Stark VE, Morse B, Shibata D, Vignesh S, Morse DL. Cell-surface markers for colon adenoma and adenocarcinoma. Oncotarget. 2016 Apr;7(14):17773-17789. Pubmedid: 26894861. Pmcid: PMC4951249.
- Kim R, Prithviraj G, Kothari N, Springett G, Malafa M, Hodul P, Kim J, Yue B, Morse B, Mahipal A. PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer. Clin Nucl Med. 2015 Nov;40(11):e501-e505. Pubmedid: 26053713. Pmcid: PMC4813735.
- Morse B, Strosberg J. Congenital Anomaly Detected During Work-up of Cystic Pancreatic Lesion. Gastroenterology. 2015 Jul;149(1):33-34. Pubmedid: 26025308.
- Cives M, Kunz P, Morse B, Schell MJ, Campos T, Nguyen PT, Nandoskar P, Khandelwal V, Strosberg J. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2015 Feb;22(1):1-9. Pubmedid: 25376618. Pmcid: PMC4643672.
- Morse B, Centeno B, Vignesh S. Autoimmune pancreatitis: updated concepts of a challenging diagnosis. Am J Med. 2014 Oct;127(10):1010.e1-1010.e9. Pubmedid: 24835039.
- Saranga-Perry V, Morse B, Centeno B, Kvols L, Strosberg J. Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series. Neuroendocrinology. 2014 Feb;97(4):318-321. Pubmedid: 23296364.
- Silva AC, Morse BG, Hara AK, Paden RG, Hongo N, Pavlicek W. Dual-Energy (Spectral) CT: Applications in Abdominal Imaging. Radiographics. 2011 Jul;31(4):1031-1046. Pubmedid: 21768237.
- Nuss GR, Morey AF, Jenkins AC, Pruitt JH, Dugi DD, Morse B, Shariat SF. Radiographic predictors of need for angiographic embolization after traumatic renal injury. J Trauma. 2009 Sep;67(3):578-582. Pubmedid: 19741403.
- Charton J, Witherspoon SR, Itani K, Jones FR, Marple B, Morse B. Natural killer/T-cell lymphoma masquerading as orbital cellulitis. Ophthal Plast Recons. 2008 Mar;24(2):143-145. Pubmedid: 18356722.
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.Learn more about our patient comments
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
- The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
- He or she may be a researcher or other type of provider that does not see patients.
- The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.